Drug Patents owned by Fresenius Kabi Usa

1. Drug name - ACETAMINOPHEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration Apr, 2030

(7 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - BORTEZOMIB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations Nov, 2032

(10 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
3.5MG/VIAL POWDER;INTRAVENOUS Prescription

3. Drug name - CASPOFUNGIN ACETATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations Dec, 2032

(10 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription
70MG/VIAL POWDER;INTRAVENOUS Prescription

4. Drug name - DILAUDID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container Apr, 2032

(9 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs Mar, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
0.2MG/ML INJECTABLE;INJECTION Prescription
1MG/ML INJECTABLE;INJECTION Prescription
2MG/ML INJECTABLE;INJECTION Prescription
4MG/ML INJECTABLE;INJECTION Discontinued
10MG/ML INJECTABLE;INJECTION Discontinued
250MG/VIAL INJECTABLE;INJECTION Discontinued

5. Drug name - DIPRIVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures Jun, 2025

(2 years from now)

Drugs and Companies using PROPOFOL ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
10MG/ML INJECTABLE;INJECTION Prescription

6. Drug name - FULVESTRANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations Feb, 2034

(11 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations Feb, 2034

(11 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations May, 2034

(11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
250MG/5ML (50MG/ML) SOLUTION;INTRAMUSCULAR Prescription

7. Drug name - LEVOTHYROXINE SODIUM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238 FRESENIUS KABI USA Levothyroxine formulations Aug, 2032

(9 years from now)

US9168239 FRESENIUS KABI USA Levothyroxine formulations Aug, 2032

(9 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations Oct, 2032

(10 years from now)

US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations Dec, 2036

(14 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations Dec, 2036

(14 years from now)

US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations Dec, 2036

(14 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MCG/VIAL POWDER;INTRAVENOUS Prescription
200MCG/VIAL POWDER;INTRAVENOUS Prescription
500MCG/VIAL POWDER;INTRAVENOUS Prescription

8. Drug name - MORPHINE SULFATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072781 FRESENIUS KABI USA Morphine formulations Mar, 2034

(11 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs Mar, 2034

(11 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations Mar, 2034

(11 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: Management of chronic pain in patients requiring opioid analgesia; treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2MG/ML (2MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
4MG/ML (4MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
5MG/ML (5MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
8MG/ML (8MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
10MG/ML (10MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription

9. Drug name - NAROPIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids May, 2023

(7 months from now)

US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids May, 2024

(1 year, 7 months from now)

US7828787 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids Oct, 2025

(3 years from now)

US7857802 FRESENIUS KABI USA Connector for medical liquid-containing packages and medical liquid-containing packages Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM/200ML (5MG/ML) SOLUTION;INJECTION Prescription
50MG/10ML (5MG/ML) SOLUTION;INJECTION Discontinued
20MG/10ML (2MG/ML) SOLUTION;INJECTION Prescription
40MG/20ML (2MG/ML) SOLUTION;INJECTION Prescription
75MG/10ML (7.5MG/ML) SOLUTION;INJECTION Discontinued
100MG/20ML (5MG/ML) SOLUTION;INJECTION Prescription
100MG/10ML (10MG/ML) SOLUTION;INJECTION Prescription
150MG/20ML (7.5MG/ML) SOLUTION;INJECTION Prescription
150MG/30ML (5MG/ML) SOLUTION;INJECTION Prescription
200MG/100ML (2MG/ML) SOLUTION;INJECTION Prescription
200MG/20ML (10MG/ML) SOLUTION;INJECTION Prescription
400MG/200ML (2MG/ML) SOLUTION;INJECTION Prescription
500MG/100ML (5MG/ML) SOLUTION;INJECTION Prescription

10. Drug name - OMEGAVEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN) Nov, 2024

(2 years from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN) Jul, 2025

(2 years from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN) Jul, 2025

(2 years from now)

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Treatment of liver disease through nutrition for patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
5GM/50ML (0.1GM/ML) EMULSION;INTRAVENOUS Prescription
10GM/100ML (0.1GM/ML) EMULSION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.